1. Home
  2. EIC vs AMRN Comparison

EIC vs AMRN Comparison

Compare EIC & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EIC
  • AMRN
  • Stock Information
  • Founded
  • EIC N/A
  • AMRN 1989
  • Country
  • EIC United States
  • AMRN Ireland
  • Employees
  • EIC N/A
  • AMRN 275
  • Industry
  • EIC Finance/Investors Services
  • AMRN Biotechnology: Pharmaceutical Preparations
  • Sector
  • EIC Finance
  • AMRN Health Care
  • Exchange
  • EIC Nasdaq
  • AMRN Nasdaq
  • Market Cap
  • EIC 287.1M
  • AMRN 189.2M
  • IPO Year
  • EIC 2019
  • AMRN 1993
  • Fundamental
  • Price
  • EIC $15.37
  • AMRN $0.46
  • Analyst Decision
  • EIC
  • AMRN Buy
  • Analyst Count
  • EIC 0
  • AMRN 1
  • Target Price
  • EIC N/A
  • AMRN N/A
  • AVG Volume (30 Days)
  • EIC 116.0K
  • AMRN 1.7M
  • Earning Date
  • EIC 11-14-2023
  • AMRN 10-30-2024
  • Dividend Yield
  • EIC 13.63%
  • AMRN N/A
  • EPS Growth
  • EIC N/A
  • AMRN N/A
  • EPS
  • EIC 0.80
  • AMRN N/A
  • Revenue
  • EIC N/A
  • AMRN $241,021,000.00
  • Revenue This Year
  • EIC N/A
  • AMRN N/A
  • Revenue Next Year
  • EIC N/A
  • AMRN N/A
  • P/E Ratio
  • EIC $20.31
  • AMRN N/A
  • Revenue Growth
  • EIC N/A
  • AMRN N/A
  • 52 Week Low
  • EIC $13.00
  • AMRN $0.43
  • 52 Week High
  • EIC $16.48
  • AMRN $1.37
  • Technical
  • Relative Strength Index (RSI)
  • EIC 35.79
  • AMRN 40.30
  • Support Level
  • EIC $15.11
  • AMRN $0.43
  • Resistance Level
  • EIC $15.35
  • AMRN $0.50
  • Average True Range (ATR)
  • EIC 0.16
  • AMRN 0.03
  • MACD
  • EIC -0.04
  • AMRN 0.00
  • Stochastic Oscillator
  • EIC 20.83
  • AMRN 30.00

About EIC Eagle Point Income Company Inc.

Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation.

About AMRN Amarin Corporation plc

Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.

Share on Social Networks: